Therapy News and Research

RSS
Dexcom G5 Mobile Continuous Glucose Monitoring System receives FDA approval

Dexcom G5 Mobile Continuous Glucose Monitoring System receives FDA approval

Shire enters into agreement with Sanquin for CINRYZE

Shire enters into agreement with Sanquin for CINRYZE

Study looks at patterns of emotion regulation in the brains of abused children

Study looks at patterns of emotion regulation in the brains of abused children

Irreversible electroporation may prolong survival rates of patients with locally advanced pancreatic cancer

Irreversible electroporation may prolong survival rates of patients with locally advanced pancreatic cancer

Jopari, One Call partner to accelerate workers' compensation workflows for medical practices

Jopari, One Call partner to accelerate workers' compensation workflows for medical practices

Dr. Sharma receives research award from ASCO to continue study on triple-negative breast cancer

Dr. Sharma receives research award from ASCO to continue study on triple-negative breast cancer

Study sheds light on fertility concerns of young breast cancer patients

Study sheds light on fertility concerns of young breast cancer patients

Mayo Clinic scientists discover potential way to reprogram cancer cells back to normalcy

Mayo Clinic scientists discover potential way to reprogram cancer cells back to normalcy

Karolinska Institutet study may lead to development of better immune-based cancer therapies

Karolinska Institutet study may lead to development of better immune-based cancer therapies

Boston Scientific receives CE Mark on MRI conditional labeling for CRT-D and ICD systems

Boston Scientific receives CE Mark on MRI conditional labeling for CRT-D and ICD systems

Ascendis Pharma's total revenue decreases 50% to €1.9 million in second quarter 2015

Ascendis Pharma's total revenue decreases 50% to €1.9 million in second quarter 2015

Esperance, MD Anderson form strategic alliance to accelerate development of anti-cancer candidate EP-100

Esperance, MD Anderson form strategic alliance to accelerate development of anti-cancer candidate EP-100

Beta-blockers improve overall survival among epithelial ovarian cancer patients

Beta-blockers improve overall survival among epithelial ovarian cancer patients

UT System Board of Regents approves new UT Southwestern Monty and Tex Moncrief Medical Center

UT System Board of Regents approves new UT Southwestern Monty and Tex Moncrief Medical Center

Cognitive factors associated with activity, participation in everyday life among people with MS

Cognitive factors associated with activity, participation in everyday life among people with MS

Stanford University launches new professional education course

Stanford University launches new professional education course

Alpha lipoic acid can stimulate telomerase with positive effects in mouse model of atherosclerosis

Alpha lipoic acid can stimulate telomerase with positive effects in mouse model of atherosclerosis

HPPI commences enrollment for Phase II(b) SCORING clinical trial for cancer treatment

HPPI commences enrollment for Phase II(b) SCORING clinical trial for cancer treatment

MTG Biotherapeutics' MTG-201 granted FDA Orphan Drug Designation for malignant mesothelioma treatment

MTG Biotherapeutics' MTG-201 granted FDA Orphan Drug Designation for malignant mesothelioma treatment

IQWiG dossier assessment finds added benefit of afatinib in patients with certain mutations

IQWiG dossier assessment finds added benefit of afatinib in patients with certain mutations

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.